Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
4.760
+0.030 (0.63%)
Nov 3, 2026, 3:36 PM EST - Market open
Savara Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
70
Market Cap
1.21B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 257.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | 400.00K | 346.00K | 640.74% |
| Dec 31, 2015 | 54.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | 300.00K | -200.00K | -40.00% |
| Dec 31, 2008 | 500.00K | - | - |
| Dec 31, 2007 | 500.00K | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Syndax Pharmaceuticals | 252.25M |
| Ascentage Pharma Group International | 94.61M |
| Verastem | 87.53M |
| Nektar Therapeutics | 54.59M |
| Silence Therapeutics | 615.00K |
SVRA News
- 13 days ago - Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment - Business Wire
- 22 days ago - Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026 - Business Wire
- 26 days ago - Savara Slides: Corporate presentation - Filings
- 27 days ago - Savara initiated with an Overweight at JPMorgan - TheFly
- 2 months ago - Savara announces presentations of Results from Phase 3 trial of Molgramostim - TheFly
- 2 months ago - Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 - Business Wire
- 2 months ago - Savara Announces New Employment Inducement Grant - Business Wire
- 2 months ago - Savara reports Q2 EPS (16c), consensus (15c) - TheFly